Cochrane · systematic review · CD012714
Medications for daytime sleepiness in individuals with idiopathic hypersomnia
Trotti, LM, Becker, LA, Friederich Murray, C, et al. · Cochrane Database of Systematic Reviews · 2021 · Cochrane Library
EpilepsyAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
14
current version
GRADE rated
14
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 0 · 0%Low 9 · 64.3%Moderate 3 · 21.4%High 2 · 14.3%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Modafinil compared to placebo for idiopathic hypersomnia
Population: idiopathic hypersomnia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Epworth Sleepiness Scale (ESS), week 3№ of participants: 101(2 RCTs) Modafinil vs placebo | no estimate extracted | NR | High |
Number of naps/week, week 3№ of participants: 99(2 RCTs) Modafinil vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Clinical Global Impression ‐ Severity (CGI‐S), change from baseline№ of participants: 30(1 RCT) Modafinil vs placebo | no estimate extracted | NR | Moderate Downgraded: imprecision |
Clinical Global Impression ‐ Change (CGI‐C), proportion much improved or very much improved at week 3 № of participants: 70 (1 RCT) Modafinil vs placebo | OR 5.14 [1.76, 15] | NR | Moderate Downgraded: imprecision |
Maintenance of Wakefulness Test (MWT), week 3№ of participants: 99(2 RCTs) Modafinil vs placebo | no estimate extracted | NR | High |
Effectiveness/performance, week 3№ of participants: 31(1 RCT) Modafinil vs placebo | no estimate extracted | NR | Moderate Downgraded: imprecision |
Number of participants with any adverse events№ of participants: 102(2 RCTs) Modafinil vs placebo | OR 1.68 [0.28, 9.94] | NR | Low Downgraded: imprecision |
Clarithromycin compared to placebo for idiopathic hypersomnia
Population: idiopathic hypersomnia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Epworth Sleepiness Scale (ESS), change from baseline№ of participants: 10(1 RCT) Clarithromycin vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Stanford Sleepiness Scale (SSS), change from baseline№ of participants: 10(1 RCT) Clarithromycin vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Average nocturnal sleep time from sleep diary, weeks 1 and 2№ of participants: 10(1 RCT) Clarithromycin vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Difficulty waking in the morning, average of weeks 1 and 2№ of participants: 10(1 RCT) Clarithromycin vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Psychomotor vigilance task (PVT) reciprocal of reaction time, change from baseline№ of participants: 10(1 RCT) Clarithromycin vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Functional Outcomes of Sleep Questionnaire (FOSQ), change from baseline№ of participants: 10(1 RCT) Clarithromycin vs placebo | no estimate extracted | NR | Low Downgraded: imprecision |
Number of participants with any adverse events№ of participants: 10(1 RCT) Clarithromycin vs placebo | OR 0.41 [0.01, 12.64] | NR | Low Downgraded: imprecision |